RVTY — Revvity, Inc.

Revvity (RVTY) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $711 million, reflecting a 3% organic growth, exceeding guidance.
• Pro Forma Adjusted EPS: $1.41, significantly above the high end of guidance, driven by strong operational performance and $16 million in tariff refunds.
• Adjusted Operating Margin: 29.3%, surpassing the 27% guidance, aided by tariff refunds and operational efficiencies.
• Free Cash Flow: $184 million, with a conversion rate of 117% of adjusted net income.
• Net Debt-to-Adjusted EBITDA: 2.5x, with gross leverage expected to drop below 3x by year-end.

2. Strategic Updates and Business Highlights

• Diagnostics Segment: Grew 11% organically, with strong performance in reproductive health and immunodiagnostics, driven by newborn screening and Genomics England contracts.
• Life Sciences Segment: Experienced a 3% organic decline, primarily due to a 20% drop in Signals software revenue, although reagents and instrumentation showed positive growth.
• AI-Driven Demand: Increased orders from both traditional and non-traditional customers linked to AI data generation, particularly for high-content screening instruments like the Opera Phenix OptIQ.
• Divestiture Update: Definitive agreement signed for the divestiture of the China immunodiagnostics business, expected to close by the end of 2027.
• Software Innovations: Launch of new products including Signals AI and Anthropic MCP connector, aimed at enhancing the Signals platform's capabilities.

3. Forward Guidance and Outlook

• Full-Year Organic Growth: Revised to 4% to 5%, up from 3% to 4%.
• Adjusted Operating Margin Guidance: Now expected at 28.7%, reflecting improved organic growth and the impact of tariff refunds.
• Adjusted EPS Guidance: Increased to a range of $5.30 to $5.40, up by $0.10 from previous guidance.
• Third Quarter Expectations: Organic growth projected at 4% to 6%, with revenue forecasted between $685 million to $700 million.

4. Challenges and Points of Concern

• Life Sciences Decline: The segment faced a 3% organic decline, primarily due to the significant drop in Signals software revenue, which is expected to recover but remains a concern.
• Competitive Pressures: The need to maintain pricing without passing on costs to customers while investing in strategic initiatives poses a challenge.
• Timing Issues: Some revenue from instrument orders spilled into Q3, potentially impacting Q2 results and creating uncertainty in short-term performance.

5. Notable Q&A Insights

• Customer Base Expansion: Increasing orders from non-traditional customers focused on AI-driven drug discovery, indicating a shift in market dynamics.
• Instrument Backlog: Strong backlog for high-content screening instruments, with expectations for improved performance in the second half of the year.
• Reagent Growth Potential: Anticipated growth in reagent sales as new instruments are placed, indicating a positive long-term outlook.
• Software Recovery Confidence: Confidence in a rebound for the software segment in the second half, driven by contract renewals and new product integrations.

Overall, Revvity's Q2 2026 results indicate strong operational performance and a positive outlook, despite challenges in the Life Sciences segment and the need for ongoing strategic investments. The company is well-positioned to capitalize on the growing demand for AI-driven solutions in preclinical R&D.